Megaphone icon ETF Database is now VettaFi. Read More >
ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • Entrepreneur ETF
    • Equity ETF
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Future ETFs
    • Gold & Silver Investing
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Modern Alpha
    • Multi-Asset
    • Multi-Factor
    • Nasdaq Investment Intelligence
    • Portfolio Strategies
    • Retirement Income
    • Smart Beta
    • Thematic Investing
    • Volatility Resource
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Videos & Podcasts
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Earnings Outshine in the Healthcare Industry
News
Share

Earnings Outshine in the Healthcare Industry

Bob CiuraOct 27, 2015
2015-10-27

Once again, it’s earnings season for corporate America. The healthcare sector takes its turn this week, with several high-profile companies set to report earnings. Overall, the sector has performed well this year, although it’s been under heat in the last few months as the broader equity markets sputter along due to fears of rising interest rates and slowing economic growth in the emerging markets.

In addition, some healthcare companies have received unwelcome attention from large investor groups, and even regulators as well. This has caused a wave of negative sentiment, casting a shadow over the industry. But, the good news is that, so far, corporate earnings are surpassing expectations in the sector. This could be a sign that the dark clouds hanging over Big Pharma’s head may soon pass.

Here are some healthcare ETFs for investors to play a recovery in Big Pharma.

Healthcare Under Scrutiny

Certain healthcare companies have come under intense scrutiny in recent weeks from hedge fund managers. For example, the financial media recently reported that Valeant Pharmaceuticals (VRX) was accused of “channel-stuffing” by short-selling investment firm Citron Research. Channel-stuffing is a practice in which a company will artificially inflate their revenue by sending retailers in its distribution network more inventory than they can sell. Valeant has aggressively defended its business model and its accounting practices, and took the additional step of asking the U.S. Securities and Exchange Commission to investigate Citron’s reporting.

This story goes to show how much of an impact can be made by raising questions over a company’s accounting. After the news, Valeant’s stock price lost one third of its value in just five trading days.


Content continues below advertisement

Earnings Widely Beating Estimates

Fortunately for the healthcare sector, there was some good news this week in the form of positive corporate earnings. A number of Big Pharma companies are reporting earnings, including Pfizer (PFE), Bristol-Myers Squibb (BMY), and Merck (MRK). Pfizer’s adjusted earnings per share reached 60 cents today, which beat analyst expectations of 51 cents per share. And Pfizer raised its forecast for the remainder of the year. Thanks to strong contributions from recently acquired Hospira, Pfizer expects 2015 adjusted earnings of $2.16 per share to $2.20 per share, up from a forecast it had updated last month to $2.04 per share to $2.10 per share. Analysts expect, on average, $2.09 per share.

Separately, Bristol-Myers Squibb reported 39 cents per share of adjusted earnings, which beat analyst expectations of 35 cents per share. Revenue also came in above forecasts. This was due to the company’s strong pipeline. Sales of its Daklinza and Sunvepra grew by $353 million, and Opdivo revenue grew by $304 million.

Lastly, Merck beat analyst expectations for quarterly profit thanks to cost cuts and strong sales of its diabetes and cancer drugs. Merck has reduced annual spending by $2.5 billion since 2012, which helped the company earn 96 cents per share last quarter. That beat analyst projections of 91 cents per share. Its diabetes drugs Januvia and Janumet collectively grew sales by 10% last quarter.

More large healthcare companies reporting this week include Gilead (GILD), Amgen (AMGN), Novo Nordisk (NVO), and Sanofi (SNY). We’ll see if these companies will outperform earnings as well.

Visit our Stock Exposure Tool to see which ETFs have the most exposure to these stocks.

How to Play Healthcare Earnings

Investors interested in buying exchange-traded funds to gain exposure to the healthcare sector more broadly have several options. There are a number of ETFs in the healthcare space, including the Health Care Select Sector SPDR ETF (XLV A) and the Vanguard Health Care ETF (VHT A+). The XLV and VHT funds are up about 3% each year-to-date. This has slightly outperformed the broader S&P 500 Index return in that time. Furthermore, the healthcare industry has outperformed the broader S&P 500 up until August of this year. It’s only recently that the industry has been under pressure.

The Bottom Line

Increasing investor and regulatory scrutiny of the healthcare industry has weighed on the sector these last few months. Negative sentiment has dragged down the major healthcare ETFs, but going forward better returns may be on the horizon. A number of Big Pharma companies like Pfizer, Bristol-Myers Squibb, and Merck are beating earnings estimates this year. Strong revenue and earnings growth from new drugs could fuel better performance for the healthcare ETFs up ahead.

Image courtesy of sscreations at FreeDigitalPhotos.net

» Popular Pages

  • Tickers
  • Articles

Jun 24

As Inflation Rises, Try Equal Weighting Equity Holdings

Jun 24

Cybersecurity Investments Could be an Opportunity

Jun 24

Diversifying During Rate Hikes With a Real Estate ETF

Jun 24

Don't Ever Bet Against the S&P 500

Jun 24

Have We Reached Rock Bottom?

Jun 24

Coinbase Poised to Launch Derivatives Product

Jun 24

Any Time is the Right Time to Begin Investing

Jun 24

American Century’s Sandra Testani

Jun 24

Exxon Demands Higher Carbon Tax: This Fund Benefits

Jun 24

Gender Matters When it Comes to Retirement Planning

QQQ

Invesco QQQ Trust

SPY

SPDR S&P 500 ETF Trust

VOO

Vanguard S&P 500 ETF

ARKK

ARK Innovation ETF

VTI

Vanguard Total Stock Market...

XLE

Energy Select Sector SPDR...

VYM

Vanguard High Dividend Yield...

IVV

iShares Core S&P 500 ETF

SCHD

Schwab US Dividend Equity ETF...

XLK

Technology Select Sector SPDR...


Content continues below advertisement

Loading Articles...
Help & Info
  • Contact Us
  • Mission Statement
  • Press
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © ETF Flows LLC
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X